布魯克在 Sierra SPR 平臺上實現高通量多路復用 HTS

用于高通量篩選 （HTS） 的 Sierra 表面等離子體共振 （SPR） Pro 系列

創新的Sierra SPR-32 Pro允許多重HTS深入了解動力學，而不會影響樣品的靈敏度和性質

通過無標記高溫超導酶對分子相互作用的SPR洞察，以支持藥物發現

布魯克 Sierra SPR-32 Pro 為生物制劑和小分子候選藥物的開發提供通量優化的檢測裝置。抗原等單一分析物可同時檢測多達 31 種捕獲抗體 （A）。同一平臺還允許通過一次實驗 （B） 針對一到三個靶標測試多達 8 種分析物。后一種設置與自動化相結合，為SPR提供了行業領先的吞吐量。 （圖示：美國商業資訊）

2022 年 2 月 7 日東部標準時間上午 07：01

波士頓--（美國商業資訊）--在SLAS2022國際會議暨展覽會上，布魯克公司（納斯達克股票代碼：BRKR）宣布推出一項多重檢測方法，將SPR的高通量篩選提升到一個新的水平。布魯克 Sierra SPR-32 Pro 的創新微流體系統提供獨特的 8x4 陣列，每次進樣可并行讀取 32 個測量傳感器點，具有出色的魯棒性。這種配置提供了高通量，同時保持了生物制劑和小分子候選藥物開發的靈活性，例如，用于測試一種抗原對抗31種抗體，8種小分子針對3種靶蛋白，每個通道一個參比。

“布魯克 SPR 系統通過我們的并行讀數（獨特的高靈敏度 SPR 檢測系統）與最先進的自動化相結合，以最高的吞吐量和數據質量為先導開發流程提供不可或缺的信息豐富的數據。”

推特這個

布魯克令人印象深刻地展示了Sierra SPR-32 Pro平臺的多重檢測能力，包括先導物開發階段典型的選擇性測定，以及針對一組碳酸酐酶（具有高度相似性的蛋白質家族）的篩選分析。這些具有挑戰性的例子通常需要對每種靶蛋白進行繁瑣的重復相同的測定，從而減慢藥物開發過程。Sierra SPR-32 Pro 的多路復用功能可將測量時間縮短多達三倍。布魯克的高靈敏度 SPR 檢測可在分析物與目標 10 之間的高分子量差異下進行測量-3，甚至支持基于片段的藥物設計。

此外，布魯克還開發了自動化 24/7 SPR 印版操作，或通過其自動化接口將 SPR 集成到 HTS 中，該接口可與來自不同供應商的通用調度軟件配合使用。布魯克的 SPR 軟件可將數據和結果無縫傳輸到下游分析軟件，例如 Genedata Screener?。

諾華生物醫學研究所（瑞士巴塞爾）、Genedata（瑞士巴塞爾）和布魯克之間的合作在應用說明“諾華通過高通量生物物理篩選應對具有挑戰性的目標”中進行了描述。在5天的總實驗時間中，針對一種靶蛋白和兩種疾病相關突變體對10，000多種化合物進行了表征。從布魯克的 SPR 軟件到 Genedata Screener? 的無縫數據傳輸將數據分析時間縮短至 2.5 小時。

巴塞爾諾華生物醫學研究所蛋白質科學小組實驗室負責人Christine Genick博士表示：“這是一項真正的合作努力，Genedata和布魯克真正加強了合作，使我們能夠突破SPR的極限。通過建立強大的自動化和全面的處理管道，我們能夠以閃電般的速度篩選和分析我們的數據。

布魯克生物制藥無標記技術總監Meike Hamester博士總結道：“布魯克SPR系統通過我們的并行讀出（獨特的高靈敏度SPR檢測系統）與最先進的自動化相結合，以最高的通量和數據質量為先導物開發過程提供不可或缺的信息豐富的數據。

關于布魯克公司（納斯達克股票代碼：BRKR）

布魯克使科學家能夠取得突破性發現并開發新的應用，從而提高人類生活質量。布魯克的高性能科學儀器以及高價值的分析和診斷解決方案使科學家能夠在分子、細胞和微觀水平上探索生命和材料。通過與客戶的密切合作，布魯克在生命科學分子和細胞生物學研究、應用和制藥應用、顯微鏡和納米分析以及工業應用中實現創新、提高生產力和客戶成功。布魯克在臨床前成像、臨床表型組學研究、蛋白質組學和多組學、空間和單細胞生物學、功能結構和凝聚物生物學以及臨床微生物學和分子診斷學方面提供差異化的、高價值的生命科學和診斷系統和解決方案。欲了解更多信息，請訪問：www.bruker.com。

Bruker Enables High-Throughput Multiplex HTS on Sierra SPR Platform

Sierra Surface Plasmon Resonance (SPR) Pro Series for High-Throughput Screening (HTS)

• Innovative Sierra SPR-32 Pro allowing multiplex HTS for insights into kinetics with no compromise in sensitivity and nature of samples

• SPR insights into molecular interactions by label-free HTS in support of drug discovery

The Bruker Sierra SPR-32 Pro offers throughput-optimized assay set-ups for the development of both biologics and small molecule drug candidates. Single analytes like an antigen can be simultaneously tested against up to 31 capture antibodies (A). The same platform also allows to test up to 8 analytes against one to three targets with a single experiment (B). The latter set-up coupled with automation provides industry-leading throughput for SPR. (Graphic: Business Wire)

• 
  

• 
  

February 07, 2022 07:01 AM Eastern Standard Time

BOSTON--(BUSINESS WIRE)--At the SLAS2022 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) is announcing a multiplexed assay taking high-throughput screening with SPR to the next level. The innovative microfluidic system of the Bruker Sierra SPR-32 Pro provides a unique 8x4 array for parallel readout of 32 measurement sensor spots per injection at exceptional robustness. This configuration offers high throughput while maintaining flexibility for the development of both, biologics and small molecule drug candidates, e.g., for testing one antigen against 31 antibodies, to 8 small molecules against 3 target proteins with a single reference per channel.

“The Bruker SPR systems provide indispensable, information-rich data for the lead development processes at highest throughput and data quality, enabled by our parallel readout, a unique high sensitivity SPR detections system, all combined with state-of-the-art automation.”

Tweet this

Bruker impressively demonstrated the multiplexing capabilities of the Sierra SPR-32 Pro platform with a selectivity assay, typical for lead development stages, and a screening assay against a set of carbonic anhydrases, a protein family with a high degree of similarity. These challenging examples typically require tedious repetitions of the same assay for each target protein, slowing down the drug development process. The multiplexing capabilities of the Sierra SPR-32 Pro reduces measurement time by up to threefold. Bruker’s highly sensitive SPR detection enables measurements at high molecular weight differences between analyte and target of 10-3, supporting even fragment-based drug design.

Moreover, Bruker has developed automated 24/7 SPR plate-handling operation, or by its automation interface for SPR integration in HTS, which works with common scheduling software from various vendors. Bruker’s SPR software features seamless transfer of data and results to downstream analysis software, e.g., to Genedata Screener?.

A collaboration between Novartis Institute of Biomedical Research (Basel, CH), Genedata (Basel, CH) and Bruker is described in the application note ‘Tackling Challenging Targets with High-Throughput Biophysical Screening at Novartis’. With a total experimental time of 5 days, more than 10,000 compounds were characterized against one target protein and two of its disease relevant mutants. The seamless data transfer from Bruker’s SPR software to Genedata Screener? reduced data analysis to 2.5 hours.

Dr. Christine Genick, Lab Head of the Protein Sciences Group at the Novartis Institute of Biomedical Research in Basel, stated: “This was a truly collaborative effort, in which Genedata and Bruker really stepped up and enabled us to push the limits of SPR. By setting up robust automation and a comprehensive processing pipeline, we were able to screen and analyze our data with lightning speed.”

Dr. Meike Hamester, Bruker Director of BioPharma Label-free Technologies, summarized: “The Bruker SPR systems provide indispensable, information-rich data for the lead development processes at highest throughput and data quality, enabled by our parallel readout, a unique high sensitivity SPR detections system, all combined with state-of-the-art automation.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.